FN
Publications
246
Views
116 661
Downloads
18 780
Supervised works
6
Items per page
1 - 246 of 246
Title Published in Access level OA Policy Year Views Downloads
A global research priority agenda to advance public health responses to fatty liver diseaseJournal of hepatology
accessLevelPublic
2023 41 5
ANGPTL4 is a potential driver of HCV-induced peripheral insulin resistanceScientific reports
accessLevelPublic
2023 106 18
HCV disease burden and population segments in SwitzerlandLiver international
accessLevelPublic
2022 153 62
Maladies infectieusesRevue médicale suisse
accessLevelPublic
2021 287 72
The never-ending debate about conflict of interests'Liver international
accessLevelPublic
2021 125 24
NAFLD and MAFLD as emerging causes of HCC: a populational studyJHEP Reports : Innovation in hepathology
accessLevelPublic
2021 211 107
Endpoints and New Options for Treatment of Chronic Hepatitis DHepatology
accessLevelPublic
2021 92 64
Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in SwitzerlandSwiss Medical Weekly
accessLevelPublic
2021 168 64
Recommandations pour le suivi des patients atteints d'hépatite C guérieSwiss Medical Forum
accessLevelPublic
2021 184 109
HDV pathogenesis: unravelling ariadne's threadViruses
accessLevelPublic
2021 160 83
Hepatitis C prevalence in the psychiatric setting: cost-effectiveness of scaling-up screening and direct-acting antiviral therapyJHEP Reports : Innovation in Hepatology
accessLevelPublic
2021 232 90
Real-world outcomes in historically underserved patients with chronic hepatitis C infection treated with Glecaprevir/PibrentasvirInfectious Diseases and Therapy
accessLevelPublic
2021 157 64
Residual risk of liver disease after hepatitis C virus eradicationJournal of Hepatology
accessLevelRestricted
2021 150 0
MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspectiveAlimentary Pharmacology and Therapeutics
accessLevelRestricted
2021 172 0
The case for simplifying and using absolute targets for viral hepatitis elimination goalsJournal of Viral Hepatitis
accessLevelRestricted
2021 158 0
Hepatitis C core antigen test as an alternative for diagnosing HCV infection: mathematical model and cost-effectiveness analysisPeerJ
accessLevelPublic
2021 258 61
The changing context of hepatitis DJournal of Hepatology
accessLevelRestricted
2021 155 0
Mir-21 Suppression Promotes Mouse HepatocarcinogenesisCancers
accessLevelPublic
2021 186 324
Hepatitis C virus: current steps toward elimination in Germany and barriers to reaching the 2030 goalHealth science reports
accessLevelPublic
2021 188 56
EASL recommendations on treatment of hepatitis C: final update of the seriesJournal of Hepatology
accessLevelRestricted
2020 209 0
Buyers' club : une alternative pour l'accès au traitement ?Revue médicale suisse
accessLevelPublic
2020 319 112
A letter of solidarity during the COVID-19 pandemicLiver International
accessLevelPublic
2020 132 61
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic hcv infection: a meta-analysisJournal of Hepatology
accessLevelPublic
2020 199 131
Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studiesJournal of Hepatology
accessLevelRestricted
2020 245 1
Reply to: "Cirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinoma"Journal of Hepatology
accessLevelPublic
2020 180 58
SARS-CoV-2 and liver damage: a possible pathogenetic linkHepatobiliary Surgery and Nutrition
accessLevelPublic
2020 172 73
Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis?Swiss Medical Weekly
accessLevelPublic
2020 292 126
Securing sustainable funding for viral hepatitis elimination plansLiver International
accessLevelRestricted
2020 275 0
Natural history of NASH and HCCLiver International
accessLevelRestricted
2020 276 1
The MD-PhD program in Geneva: a 10-year analysis of graduate demographics and outcomesBMC Medical Education
accessLevelPublic
2020 227 193
All-Cause mortality and causes of death in the Swiss Hepatitis C Cohort Study (SCCS)Open Forum Infectious Diseases
accessLevelPublic
2020 297 137
Modelling the Impact and Cost-Effectiveness of Extended Screening and Treatment with Direct-Acting Antivirals in a Swiss Custodial SettingClinical Infectious Diseases
accessLevelPublic
2019 356 262
Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis c patientsPLOS ONE
accessLevelPublic
2019 367 128
Interleukin-1 receptor antagonist modulates liver inflammation and fibrosis in mice in a model-dependent mannerInternational Journal of Molecular Sciences
accessLevelPublic
2019 447 174
A review on hepatitis D: from virology to new therapiesJournal of Advanced Research
accessLevelPublic
2019 386 215
Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort StudyPLOS ONE
accessLevelPublic
2019 398 185
Devil hepatitis D: an orphan disease or largely underdiagnosed?Gut
accessLevelRestricted
2019 344 0
Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: a pooled analysis of clinical trialsLiver International
accessLevelPublic
2019 240 58
Very low hepatitis C viral loads in treatment-naïve persons: do they compromise hepatitis C virus antigen testing?Clinical Infectious Diseases
accessLevelPublic
2019 448 132
Programme national de lutte contre le VIH, les IST et l'hépatite virale: unir les forces contre le VIH et les hépatites viralesBulletin des médecins suisses
accessLevelPublic
2019 376 149
Identification of an endoglin variant associated with HCV-related liver fibrosis progression by next-generation sequencingFrontiers in Genetics
accessLevelPublic
2019 265 95
Natural history of hepatic and extrahepatic hepatitis C virus diseases and impact of interferon-free HCV therapyCold Spring Harbor Perspectives in Medicine
accessLevelRestricted
2019 270 2
Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidatesClinical Gastroenterology and Hepatology
accessLevelRestricted
2019 321 0
Activation of the oncogenic miR-21-5p promotes HCV replication and steatosis induced by the viral core 3a proteinLiver International
accessLevelPublic
2019 385 213
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysisJournal of Viral Hepatitis
accessLevelPublic
2019 265 106
Nonalcoholic fatty liver disease burdenSwiss Medical Weekly
accessLevelPublic
2019 247 112
Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regionsSwiss Medical Weekly
accessLevelPublic
2019 363 252
Tolerogenic propreties of liver macrophages in non-alcoholic steatohepatitisLiver International
accessLevelPublic
2019 368 378
Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in SwitzerlandSwiss Medical Weekly
accessLevelPublic
2019 1 059 267
Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: A cost-effectiveness analysisJournal of Viral Hepatitis
accessLevelRestricted
2019 376 1
The heavy burden of hepatitis D in UzbekistanLiver International
accessLevelRestricted
2019 282 0
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling studyThe Lancet Gastroenterology & Hepatology
accessLevelRestricted
2018 295 0
Hepatitis B prevalence, risk factors, infection awareness and disease knowledge among inmates: a cross-sectional study in Switzerland's largest pre-trial prisonJournal of Global Health
accessLevelPublic
2018 352 173
Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH)Hepatology
accessLevelPublic
2018 410 445
Collagen proportionate area correlates to hepatic venous pressure gradient in non-abstinent cirrhotic patients with alcoholic liver diseaseWorld Journal of Hepatology
accessLevelPublic
2018 395 270
Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030Journal of Hepatology
accessLevelPublic
2018 918 314
Deficient natural killer cell NKp30-mediated function and altered NCR3 splice variants in hepatocellular carcinomaHepatology
accessLevelRestricted
2018 440 0
Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countriesAntiviral Research
accessLevelRestricted
2018 387 0
A buyers' club to improve access to hepatitis C treatment for vulnerable populationsSwiss Medical Weekly
accessLevelPublic
2018 1 130 393
EASL Clinical Practice Guidelines on hepatitis E virus infectionJournal of Hepatology
accessLevelRestricted
2018 320 2
The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic diseaseJournal of Viral Hepatitis
accessLevelPublic
2018 282 145
Coinfections between Persistent Parasitic Neglected Tropical Diseases and Viral Infections among Prisoners from Sub-Saharan Africa and Latin AmericaJournal of Tropical Medicine
accessLevelPublic
2018 659 244
Expert opinion on the management of renal manifestations of chronic HCV infectionAntiviral Therapy
accessLevelRestricted
2018 320 0
EASL Recommendations on Treatment of Hepatitis C 2018Journal of Hepatology
accessLevelRestricted
2018 292 0
Combler les lacunes dans les tests de dépistage de l'hépatiteBulletin des médecins suisses
accessLevelPublic
2018 412 148
Expanded benefits of curing the extrahepatic manifestations of HCV infectionGut
accessLevelPublic
2018 267 185
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosisHepatology
accessLevelRestricted
2018 245 0
Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policiesJournal of Hepatology
accessLevelRestricted
2018 433 1
Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?PLOS ONE
accessLevelPublic
2018 354 166
Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic reviewJournal of Viral Hepatitis
accessLevelRestricted
2018 471 0
Cardiovascular Manifestations of Hepatitis C VirusClinics in Liver Disease
accessLevelRestricted
2017 446 2
Hépatite B : nouvelles recommandations de prise en chargeRevue médicale suisse
accessLevelRestricted
2017 492 2
Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling studyThe Lancet Gastroenterology & Hepatology
accessLevelRestricted
2017 268 0
Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A reviewJournal of Advanced Research
accessLevelPublic
2017 462 299
Access to hepatitis C treatment for patients in drug substitution programmes: the fight is far from overSwiss Medical Weekly
accessLevelPublic
2017 391 150
Estimating HCV disease burden-volume 4 (editorial)Journal of Viral Hepatitis
accessLevelRestricted
2017 346 0
Extrahepatic manifestations in hepatitis C virus infectionJournal of Advanced Research
accessLevelPublic
2017 398 105
Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030Swiss Medical Weekly
accessLevelPublic
2017 887 221
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling studyThe Lancet Gastroenterology & Hepatology
accessLevelRestricted
2017 284 0
Hepatic protein tyrosine phosphatase receptor gamma links obesity-induced inflammation to insulin resistanceNature Communications
accessLevelPublic
2017 1 475 383
The impact of hepatitis C virus outside the liver: Evidence from AsiaLiver international
accessLevelRestricted
2017 394 1
Editor's noteLiver International
accessLevelRestricted
2017 172 0
Hépatites B et C : nouveaux traitementsRevue médicale suisse
accessLevelRestricted
2017 370 0
Health-related quality of life in chronic HCV-infected patients switching to pegylated-interferon-free regimens (ARNS CO20 CUPIC cohort study and SIRIUS trial)The Patient - Patient-Centered Outcomes Research
accessLevelRestricted
2017 233 1
A Systematic Review and Meta-Analysis of HCV ClearanceLiver international
accessLevelRestricted
2017 500 1
Nucleic acid polymers: much-needed hope for hepatitis D?The Lancet Gastroenterology & Hepatology
accessLevelRestricted
2017 334 1
BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver diseaseOncotarget
accessLevelRestricted
2017 513 2
Trends in hepatitis C-related mortality in SwitzerlandJournal of Hepatology
accessLevelPublic
2017 1 140 575
The negative impact of HBV/HCV coinfection on cirrhosis and its consequencesAlimentary Pharmacology and Therapeutics
accessLevelRestricted
2017 407 0
Hepatitis C Virus Increases Occludin Expression via the Upregulation of Adipose Differentiation-Related ProteinPloS one
accessLevelPublic
2016 1 120 208
Effect of quercetin on hepatitis C virus life cycle: from viral to host targetsScientific Reports
accessLevelPublic
2016 345 108
Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genesGut
accessLevelRestricted
2016 319 1
Quels espoirs pour l'hépatite delta ?Revue médicale suisse
accessLevelRestricted
2016 389 1
Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening RecommendationsPloS one
accessLevelPublic
2016 552 507
Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirinJournal of hepatology
accessLevelRestricted
2016 475 3
The hepatitis delta virus: Replication and pathogenesisJournal of hepatology
accessLevelRestricted
2016 503 2
Phosphatase and tensin homolog is a differential diagnostic marker between nonalcoholic and alcoholic fatty liver diseaseWorld journal of gastroenterology
accessLevelRestricted
2016 552 6
Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric SurgeryClinical gastroenterology and hepatology
accessLevelRestricted
2016 476 0
A significant effect of the killer cell immunoglobulin-like receptor ligand human leucocyte antigen-C on fibrosis progression in chronic C hepatitis with or without liver transplantationLiver international
accessLevelRestricted
2016 492 1
Drug Pricing Evolution in Hepatitis CPloS one
accessLevelPublic
2016 1 303 580
Corrigendum: reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genesNature communications
accessLevelPublic
2015 520 137
ABO incompatible kidney transplantation from an anti-hepatitis C virus antibody-positive RNA-negative donor into an anti-hepatitis C virus antibody-negative recipientTransplant international
accessLevelRestricted
2015 613 1
Modeling the Health and Economic Burden of Hepatitis C Virus in SwitzerlandPloS one
accessLevelPublic
2015 559 1 293
Birth cohort distribution and screening for viraemic hepatitis C virus infections in SwitzerlandSchweizerische medizinische Wochenschrift
accessLevelPublic
2015 554 202
The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patientsJournal of Viral Hepatitis
accessLevelRestricted
2015 257 0
Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis CPloS one
accessLevelPublic
2015 637 296
A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearanceHepatology
accessLevelRestricted
2015 294 0
Are statins a remedy for all seasons?Journal of hepatology
accessLevelPublic
2015 588 214
Extrahepatic morbidity and mortality of chronic hepatitis CGastroenterology
accessLevelRestricted
2015 430 0
The evolutionary patterns of hepatitis C virus subtype 2a and 6a isolates linked to an outbreak in China in 2012Virology
accessLevelRestricted
2015 480 0
Impact of IL28B, APOH and ITPA polymorphisms on efficacy and safety of TVR- or BOC-based triple therapy in treatment-experienced HCV-1 patients with compensated cirrhosis from the ANRS CO20_CUPIC studyPLOS ONE
accessLevelPublic
2015 230 131
Repenser la politique de remboursement des agents antiviraux directs contre l'hépatite C chroniqueRevue médicale suisse
accessLevelRestricted
2015 475 1
Extrahepatic manifestations of HCVMinerva gastroenterologica e dietologica
2015 499 0
The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infectionAlimentary pharmacology & therapeutics
accessLevelRestricted
2014 561 0
Is genotype 3 of the hepatitis C virus the new villain ?Hepatology
accessLevelRestricted
2014 282 0
Clinical significance of the CCR5delta32 allele in hepatitis CPloS one
accessLevelPublic
2014 496 196
HCV 3a core protein increases lipid droplet cholesteryl ester content via a mechanism dependent on sphingolipid biosynthesisPloS one
accessLevelPublic
2014 537 206
Curbing hepatitis C virus spread in EgyptThe Lancet. Global health
accessLevelRestricted
2014 527 0
Historical epidemiology of hepatitis C virus (HCV) in selected countriesJournal of viral hepatitis
accessLevelRestricted
2014 561 1
Hepatitis D virus coinfection and superinfectionCold Spring Harbor perspectives in medicine
2014 440 0
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigmJournal of viral hepatitis
accessLevelRestricted
2014 546 1
The impact of obesity and metabolic syndrome on chronic hepatitis CClinics in liver disease
2014 500 0
Origin of hepatitis C virus genotype 3 in Africa as estimated through an evolutionary analysis of the full-length genomes of nine subtypes, including the newly sequenced 3d and 3eJournal of general virology
accessLevelRestricted
2014 503 0
EASL Clinical Practice Guidelines: management of hepatitis C virus infectionJournal of hepatology
accessLevelRestricted
2014 559 0
Transplantation cellulaire : traitements actuels et perspectives d'avenirRevue médicale suisse
accessLevelRestricted
2014 809 14
Does telaprevir possess a direct antidiabetic effect?Liver international
accessLevelRestricted
2014 554 0
Novel Approach Identifies SNPs in SLC2A10 and KCNK9 with Evidence for Parent-of-Origin Effect on Body Mass IndexPLOS genetics
accessLevelPublic
2014 674 1 210
Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseasesJournal of hepatology
accessLevelPublic
2014 530 239
Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patientsLiver international
accessLevelRestricted
2014 514 0
Epidemiology of hepatitis C in EuropeDigestive and Liver Disease
accessLevelPublic
2014 528 228
Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genesNature communications
accessLevelPublic
2014 566 1 172
Insulin resistance, non-alcoholic fatty liver disease and hepatitis C virus infectionReviews on recent clinical trials
2014 519 0
Strategies to manage hepatitis C virus (HCV) disease burdenJournal of viral hepatitis
accessLevelRestricted
2014 539 1
Hepatitis C in 2013: HCV causes systemic disorders that can be curedNature reviews. Gastroenterology & hepatology
accessLevelRestricted
2014 567 2
Morbidité et mortalité extrahépatiques associées à l'infection par le virus de l'hépatite CRevue médicale suisse
accessLevelRestricted
2014 518 1
Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma developmentPloS one
accessLevelPublic
2013 622 589
PTEN protein phosphatase activity regulates hepatitis C virus secretion through modulation of cholesterol metabolismJournal of hepatology
accessLevelRestricted
2013 639 2
Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinomaJournal of hepatology
accessLevelRestricted
2013 594 0